<!--
  Canonical interactive URL: https://www.flywayhealth.com/research/gi-january-reset
  Source of truth: src/components/research/studies/gi-january-reset.astro
-->

# Why GI Patients Already on Therapy Get Stuck in January

**Flyway Sonar · Patient Services**

In early 2026, patients already on a GI therapy came back for their refill. About one in ten had it rejected, and most of them went months without it. Most had kept the same plan, and a recent approval did not protect them. The losses kept coming into the spring.

*Based on open and closed pharmacy, medical, and remit claims covering more than 330 million lives.*

---

Every January, patient services teams re-verify benefits, help patients with new deductibles, and work through formulary changes. Yet the standard metrics, such as time to first fill and first-submission approval rate, center on new patients.

This paper looks at patients already on therapy. They filled a GI therapy in late 2025, and their insurance paid for it. Then they came back for a refill in early 2026. **Any patient lost here is one the brand had already won.**

We followed patients on two branded constipation therapies that plans typically manage with prior authorization or step therapy. For comparison, we tracked generic lubiprostone, which treats the same condition and is managed less tightly. We call a patient stuck when their refill claim was rejected and no claim for the therapy was paid for the rest of that quarter.

**What we found**

- **About one in ten patients who came back for a refill between January and March 2026 got stuck,** more than double the rate in fall 2025.
- **Most of that rise came from patients who kept the same plan.** A recent approval did not protect them.
- **A paid January refill was not the end.** Some patients were rejected by their plan at a later refill, often the next one, and went months without their therapy.
- **Most patients who got stuck did not switch.** They went without, while still filling other prescriptions, many at the same pharmacy.

## One in ten got stuck, more than double the rate in fall 2025

About one in ten patients who came back for a refill between January and March got stuck. In fall 2025 (October through December), about one in twenty-five did. The jump in stuck patients showed up in both commercial plans and Medicare. Patients on the generic, measured the same way, stayed under 2% in both seasons.

Most stuck patients went months without their therapy. **By the end of June, about four in five still did not have it back.**

Could these patients simply be missing from the data? Unlikely. Nearly all of them kept filling other prescriptions or seeing prescribers in the same data, many at the same pharmacy that had rejected their refill. And the generic showed no such jump.

Cost does not appear to be the main driver either. Abandonment at the counter, which usually reflects cost, rose in January for the generic too, and far less than rejections did. Patients filling the most other prescriptions, who tend to reach their out-of-pocket limits first, saw about the same jump as everyone else.

## Same plan, recent approval, still stuck

When patients are lost in January, the usual explanations are that they changed insurance or that their plan tightened coverage. Both happened. Neither appears to explain most of the losses.

Plan changes jump at the start of the year, most sharply in Medicare. Patients who changed plans got stuck more often in any season. **Yet compared with the fall, about seven in ten of the additional stuck patients had kept the same plan.** In the fall, staying on the same plan protected patients well. In January, it protected them far less.

**These patients would have passed the usual checks.** Their plans were still paying for the same therapy for most other members, so a check of the plan’s coverage would have shown the therapy as covered. Almost half had another prescription paid by that same plan within a month of the rejection. Many also had an approval from the past year. Prior authorizations for these therapies often run a year or more, yet patients approved in October or November got stuck at least as often as patients approved in the spring or summer. And patients whose other prescriptions had filled smoothly all fall got stuck nearly as often as those who had trouble with them.

That fits plans re-checking existing patients when the plan year turns. For many of these patients, a coverage check, an approval date, and their record with other prescriptions would all have looked fine.

It wasn’t a new prescription or a new prescriber, either. More than half of the January increase came from refills of an existing prescription, and nearly all of it came from patients whose prescriber hadn’t changed.

## A paid January refill was not the end

Some patients got through January and looked fine, then were rejected at a later refill, usually the next one or the one after, on the same plan that had just paid. This happened far more on the branded therapies than on the generic. **For every two patients stuck in January, about one more lost access this way in the spring.**

It happened more often, and sooner, when the January refill was shorter than the patient’s usual supply. One possible reason is a temporary transition supply. Medicare plans generally must provide one when a member’s therapy is dropped or newly restricted, and some commercial plans offer their own.

Rejections that came in February and March were also harder to fix than January’s.

## They did not switch. They went without.

A brand team’s first question about lost patients is usually whether they moved to a competitor. Most did not.

Only about one in six switched to another prescription for the same condition. About one in five had their own therapy back by the end of June. **More than half filled nothing for their condition that claims could see.**

They had not left care. Among patients whose rejected refill never went back in, many picked up another prescription at their normal pharmacy the same day or within a month.

> **They were still within reach.**

## What to do before January 2027

**Patient services and hub teams**

- **Don’t rely on the approval date.** In December, re-check patients approved this year, along with patients changing plans. A patient approved this fall can still be rejected in January.

  Start with patients who show several warning signs:
  - a refill rejected this fall, especially one still unfilled in mid-December;
  - an approval needed this year;
  - a plan that turned down most new patients’ first claims this year.

  Patients with several of these signs were three to five times as likely to get stuck as patients with none. Flag them to the prescriber’s office so any prior authorization or exception request is ready to submit on the first business day of the year. Stuck patients clustered in a specific set of practices: about 50 practices accounted for a disproportionate share of stuck patients relative to their overall volume.
- **Give a rejected refill the same urgency as a new start.** About one in four never went back in within a month, and most patients who recovered did so within a few weeks.
- **Watch the next refill through March,** especially after a shorter-than-usual January supply.
- **Contact the prescriber about patients who went without.** Most are still in care and have not started another prescription for their condition.

**Field reimbursement teams.** In December, tell offices that a fall approval may not carry into January, and that a short January fill can mean a rejection at the next refill. Start with the practices that have the most patients showing the warning signs. Don’t skip small offices. In commercial plans, offices handling only a few rejections at a time fixed about two in three in the fall, but only about half in January, no better than the busiest offices. Stay engaged through March, when rejections were harder to fix.

**Market access teams.** Most stuck patients were on plans that kept paying for the therapy for other members. Ask whether contracts keep patients already on therapy approved when the plan year turns, and how long any transition supply lasts.

## The takeaway

The January reset also hits the patients a brand has already won. Many were on the same plan. Many had been approved earlier in the year. For some, the trouble did not start until February or March. Most who got stuck stayed in care and can still be reached.

*Flyway Health’s Patient Services Sonar tracks these signals every month, by office, plan, and pharmacy, throughout the year.*

## Limits

These findings come from claims. The reasons we give are inferred from patterns in the claims, not observed directly.

- Free drug from manufacturer programs, cash purchases, samples, and over-the-counter products mostly do not appear in claims. Some stuck patients may have received free drug or used an over-the-counter product. Either way, their plan was not paying.
- Approvals are inferred from claims: a rejection followed by a paid fill within two months. Rejections for refilling too early don’t count. Claims do not show the paperwork.
- Plans are identified from the routing codes on each claim, plus group codes where available.
- The most recent months of data are still filling in.

## How we did this

We used open and closed pharmacy claims, plus medical claims for office visits, from a source covering more than 330 million lives. We followed a stable sub-cohort of commercial and Medicare patients with a paid fill of one of two branded constipation therapies in October through December 2025, into mid-2026.

We compared them with two groups:

- patients on generic lubiprostone over the same months;
- patients on the same therapies who filled in July through September 2025 and came back in October through December.

A patient counted as coming back when we could see a claim for the therapy, paid or rejected. For the fall comparison, we excluded a one-time batch of September 2025 claims for one therapy.
